Arcturus Therapeutics Holdings Inc. (ARCT)
NGM · Healthcare · Biotechnology
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 24.5M | 14.2M | 3.1M | 610K |
| Operating Income | -11.6M | -16.5M | -31.3M | -28.9M |
| Net Income | -9.2M | -13.4M | -29.1M | -27.0M |
| Diluted EPS | $-0.34 | $-0.49 | $-1.03 | $-0.95 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 205.8M | 157.7M | 138.4M | 67.2M |
| Operating Income | 12.2M | -78.2M | -95.7M | -76.3M |
| Net Income | 9.3M | -29.7M | -80.9M | -65.8M |
| Diluted EPS | $0.35 | $-1.00 | $-3.00 | $-2.40 |